Adenosine receptor agonists
- 1 April 2002
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 12 (4) , 489-501
- https://doi.org/10.1517/13543776.12.4.489
Abstract
Adenosine, a naturally-occurring nucleoside, modulates a variety of physiological and pathophysiological processes. The effects of adenosine are mediated via a family of cell surface G-protein-coupled receptors designated into four subtypes, A1, A2A, A2B and A3. The adenosine receptors have widespread tissue distribution and are often co-expressed in the same cell type. Research on adenosine receptors over the past few decades has resulted in the molecular cloning of the four subtypes from multiple species, significant progress in identifying selective agonists and antagonists and an increased understanding of the particular roles adenosine receptor subtypes play in physiological processes. This knowledge has continued to fuel considerable interest in pursuing adenosine receptors as therapeutic targets. For example, adenosine receptor agonists have been proposed for the treatment of heart arrhythmias, inflammatory diseases and in diagnosing coronary artery disease. In general, adenosine receptor agonists ...Keywords
This publication has 17 references indexed in Scilit:
- Recent advances in adenosine receptor antagonist researchExpert Opinion on Therapeutic Patents, 2001
- The A3 Adenosine Receptor as a New Target for Cancer Therapy and ChemoprotectionExperimental Cell Research, 2001
- Adenosine Receptor Ligands-Recent Developments Part I. AgonistsCurrent Medicinal Chemistry, 2000
- Adenosine receptors and their ligandsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 2000
- Structure and function of adenosine receptors and their genesNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 2000
- Selective A2a receptor agonists as inhibitors of cellular activationExpert Opinion on Therapeutic Patents, 2000
- A3 Adenosine Receptor Ligands: History and PerspectivesMedicinal Research Reviews, 2000
- A1 and A3 adenosine receptor agonists: an overviewExpert Opinion on Therapeutic Patents, 1999
- A comparison of an A1 adenosine receptor agonist (CVT‐510) with diltiazem for slowing of AV nodal conduction in guinea‐pigBritish Journal of Pharmacology, 1999
- Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functionsTrends in Pharmacological Sciences, 1994